2025
A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.
Roeland E, Tejani M, Cheung E, Dincman T, Lohiya V, Agarwal R, Sajid S, Gabayan A, Thumar J, Jin B, Lebedinsky C, Braendle E, Zuniga R. A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps12142.Peer-Reviewed Original ResearchGDF-15Multicenter phase 1b studyStandard-of-care therapyProportion to disease severityEscalating dose cohortsDose-limiting toxicityPhase 1b studyDose-escalation studyPathogenesis of cachexiaGDF-15 expressionRisk of side effectsAnti-drug antibodiesHigher risk of deathOff-label treatmentFDA-approved therapiesTreating cancer cachexiaAnimal cancer modelsPhase 1 healthy volunteer studyCirculating GDF-15Body weight regulationReverse weight lossRisk of deathYears of ageIgG1 monoclonal antibodyPatient-reported outcomes
2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Parikh M, Tangen C, Hussain M, Gupta S, Callis S, Jo Y, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynski R, Bryce A, Lin D, Quinn D, Lerner S, Thompson I, Dorff T, Lara P, Agarwal N. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. European Urology Oncology 2024, 7: 1097-1104. PMID: 38523017, PMCID: PMC12037053, DOI: 10.1016/j.euo.2024.03.001.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerProstate-specific antigenAndrogen deprivation therapyProstate-specific antigen levelOverall survivalProstate cancerDeprivation therapyComplete responseAntigen levelsNo responseTreatment of metastatic hormone-sensitive prostate cancerLow prostate-specific antigen levelsResponse to androgen deprivation therapyAssociated with improved OSPSA responsePhase 3 randomized trialPhase 3 clinical trialsEarly identification of patientsAssociated with OSHigher risk of deathIdentification of patientsResponse to treatmentRisk of deathOS association
2023
Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes
How J, Leiva O, Marneth A, Kamaz B, Kim C, Weeks L, Wazir M, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood 2023, 142: 4568. DOI: 10.1182/blood-2023-179324.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsEssential thrombocythemiaVariant allele fractionMyeloproliferative neoplasmsPolycythemia veraAcute myeloid leukemiaHistory of atherosclerotic diseaseMF patientsCV-RFCardiovascular risk factorsRisk of deathOverall survivalRisk factorsMPN diagnosisLeukemia progressionArterial thrombosisGenomic profilingHazard ratioAssociated with increased risk of deathAssociated with adverse outcomesAssociated with higher risk of deathAtherosclerotic diseaseAssociated with increased riskHigher risk of deathAssociated with higher riskIntermittent Hypoxemia and Bronchopulmonary Dysplasia with Pulmonary Hypertension in Preterm Infants.
Gentle S, Travers C, Nakhmani A, Indic P, Carlo W, Ambalavanan N. Intermittent Hypoxemia and Bronchopulmonary Dysplasia with Pulmonary Hypertension in Preterm Infants. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 899-907. PMID: 36449386, PMCID: PMC10111996, DOI: 10.1164/rccm.202203-0580oc.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasia-associated pulmonary hypertensionIntermittent hypoxemiaHypoxemic eventsReceiver Operating CharacteristicPreterm infantsPulmonary hypertensionControl subjectsWeeks 6 daysExtremely preterm infantsWeeks 0 daysHigher risk of deathIdentification of infantsCase-control studyRisk of deathBronchopulmonary dysplasiaDesaturation frequencyEchocardiographic dataPostnatal dayBedside biomarkersIH eventsHigh riskInfantsHypoxemiaHypertensionLong duration
2020
Characterization of Myocardial Injury in Patients With COVID-19
Giustino G, Croft L, Stefanini G, Bragato R, Silbiger J, Vicenzi M, Danilov T, Kukar N, Shaban N, Kini A, Camaj A, Bienstock S, Rashed E, Rahman K, Oates C, Buckley S, Elbaum L, Arkonac D, Fiter R, Singh R, Li E, Razuk V, Robinson S, Miller M, Bier B, Donghi V, Pisaniello M, Mantovani R, Pinto G, Rota I, Baggio S, Chiarito M, Fazzari F, Cusmano I, Curzi M, Ro R, Malick W, Kamran M, Kohli-Seth R, Bassily-Marcus A, Neibart E, Serrao G, Perk G, Mancini D, Reddy V, Pinney S, Dangas G, Blasi F, Sharma S, Mehran R, Condorelli G, Stone G, Fuster V, Lerakis S, Goldman M. Characterization of Myocardial Injury in Patients With COVID-19. Journal Of The American College Of Cardiology 2020, 76: 2043-2055. PMID: 33121710, PMCID: PMC7588179, DOI: 10.1016/j.jacc.2020.08.069.Peer-Reviewed Original ResearchConceptsIn-Hospital MortalityMyocardial injuryEchocardiographic abnormalitiesVentricular dysfunctionDiastolic dysfunction grade IIGlobal left ventricular dysfunctionAssociated with increased in-hospital mortalityTime of clinical presentationLeft ventricular wall motion abnormalitiesAssociated with higher risk of deathCardiac structural abnormalitiesRight ventricular dysfunctionVentricular wall motion abnormalitiesRates of in-hospital mortalityAssociated with myocardial injuryHigher risk of deathLaboratory-confirmed COVID-19Associated with higher riskMulticenter cohort studyWall motion abnormalitiesMechanisms of myocardial injuryRisk of deathPrognostic impactClinical presentationPericardial effusionMapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
Collaborators L, Reiner R, Wiens K, Deshpande A, Baumann M, Lindstedt P, Blacker B, Troeger C, Earl L, Munro S, Abate D, Abbastabar H, Abd-Allah F, Abdelalim A, Abdollahpour I, Abdulkader R, Abebe G, Abegaz K, Abreu L, Abrigo M, Accrombessi M, Acharya D, Adabi M, Adebayo O, Adedoyin R, Adekanmbi V, Adetokunboh O, Adhena B, Afarideh M, Ahmadi K, Ahmadi M, Ahmed A, Ahmed M, Ahmed R, Ajumobi O, Akal C, Akalu T, Akanda A, Alamene G, Alanzi T, Albright J, Rabanal J, Alemnew B, Alemu Z, Ali B, Ali M, Alijanzadeh M, Alipour V, Aljunid S, Almasi A, Almasi-Hashiani A, Al-Mekhlafi H, Altirkawi K, Alvis-Guzman N, Alvis-Zakzuk N, Amare A, Amini S, Amit A, Andrei C, Anegago M, Anjomshoa M, Ansari F, Antonio C, Antriyandarti E, Appiah S, Arabloo J, Aremu O, Armoon B, Aryal K, Arzani A, Asadi-Lari M, Ashagre A, Atalay H, Atique S, Atre S, Ausloos M, Avila-Burgos L, Awasthi A, Awoke N, Quintanilla B, Ayano G, Ayanore M, Ayele A, Aynalem Y, Azari S, Babaee E, Badawi A, Bakkannavar S, Balakrishnan S, Bali A, Banach M, Barac A, Bärnighausen T, Basaleem H, Bassat Q, Bayati M, Bedi N, Behzadifar M, Behzadifar M, Bekele Y, Bell M, Bennett D, Berbada D, Beyranvand T, Bhat A, Bhattacharyya K, Bhattarai S, Bhaumik S, Bijani A, Bikbov B, Biswas R, Bogale K, Bohlouli S, Brady O, Bragazzi N, Briko N, Briko A, Nagaraja S, Butt Z, Campos-Nonato I, Rincon J, Cárdenas R, Carvalho F, Castro F, Chansa C, Chatterjee P, Chattu V, Chauhan B, Chin K, Christopher D, Chu D, Claro R, Cormier N, Costa V, Damiani G, Daoud F, Dandona L, Dandona R, Darwish A, Daryani A, Das J, Gupta R, Dasa T, Davila C, Weaver N, Davitoiu D, De Neve J, Demeke F, Demis A, Demoz G, Denova-Gutiérrez E, Deribe K, Desalew A, Dessie G, Dharmaratne S, Dhillon P, Dhimal M, Dhungana G, Diaz D, Ding E, Diro H, Djalalinia S, Phuc H, Doku D, Dolecek C, Dubey M, Dubljanin E, Adema B, Dunachie S, Durães A, Duraisamy S, Effiong A, Eftekhari A, Sayed I, Zaki M, Tantawi M, Elemineh D, El-Jaafary S, Elkout H, Elsharkawy A, Enany S, Endalamfaw A, Endalew D, Eskandarieh S, Esteghamati A, Etemadi A, Farag T, Faraon E, Fareed M, Faridnia R, Farioli A, Faro A, Farzam H, Fazaeli A, Fazlzadeh M, Fentahun N, Fereshtehnejad S, Fernandes E, Filip I, Fischer F, Foroutan M, Francis J, Franklin R, Frostad J, Fukumoto T, Gayesa R, Gebremariam K, Gebremedhin K, Gebremeskel G, Gedefaw G, Geramo Y, Geta B, Gezae K, Ghashghaee A, Ghassemi F, Gill P, Ginawi I, Goli S, Gomes N, Gopalani S, Goulart B, Grada A, Gugnani H, Guido D, Guimares R, Guo Y, Gupta R, Gupta R, Hafezi-Nejad N, Haile M, Hailu G, Haj-Mirzaian A, Haj-Mirzaian A, Hall B, Handiso D, Haririan H, Hariyani N, Hasaballah A, Hasan M, Hasanzadeh A, Hassankhani H, Hassen H, Hayelom D, Heidari B, Henry N, Herteliu C, Heydarpour F, de Hidru H, Hoang C, Hoogar P, Hoseini-Ghahfarokhi M, Hossain N, Hosseini M, Hosseinzadeh M, Househ M, Hu G, Humayun A, Hussain S, Ibitoye S, Ilesanmi O, Ilic M, Inbaraj L, Irvani S, Islam M, Iwu C, Jaca A, Balalami N, Jahanmehr N, Jakovljevic M, Jalali A, Jayatilleke A, Jenabi E, Jha R, Jha V, Ji J, Jia P, Johnson K, Jonas J, Jozwiak J, Kabir A, Kabir Z, Kahsay A, Kalani H, Kanchan T, Matin B, Karch A, Karki S, Kasaeian A, Kasahun G, Kayode G, Karyani A, Keiyoro P, Ketema D, Khader Y, Khafaie M, Khalid N, Khalil A, Khalil I, Khalilov R, Khan N, Khan E, Khan G, Khan J, Khatab K, Khater A, Khater M, Khatony A, Khayamzadeh M, Khazaei M, Khazaei S, Khodamoradi E, Khosravi M, Khubchandani J, Kiadaliri A, Kim Y, Kimokoti R, Kisa S, Kisa A, Kissoon N, Kondlahalli S, Kosek M, Koyanagi A, Kraemer M, Krishan K, Kugbey N, Kumar G, Kumar M, Kumar P, Kusuma D, La Vecchia C, Lacey B, Lal A, Lal D, Lami F, Lansingh V, Lasrado S, Lee P, Leili M, Lenjebo T, Levine A, Lewycka S, Li S, Linn S, Lodha R, Longbottom J, Lopukhov P, Magdeldin S, Mahasha P, Mahotra N, Malta D, Mamun A, Manafi N, Manafi F, Manda A, Mansournia M, Mapoma C, Marami D, Marczak L, Martins-Melo F, März W, Masaka A, Mathur M, Maulik P, Mayala B, McAlinden C, Mehndiratta M, Mehrotra R, Mehta K, Meles G, Melese A, Memish Z, Mena A, Menezes R, Mengesha M, Mengistu D, Mengistu G, Meretoja T, Miazgowski B, Mihretie K, Miller-Petrie M, Mills E, Mir S, Mirabi P, Mirrakhimov E, Mohamadi-Bolbanabad A, Mohammad K, Mohammad Y, Mohammad D, Darwesh A, Mezerji N, Mohammadifard N, Mohammed A, Mohammed S, Mohammed J, Mohebi F, Mokdad A, Monasta L, Moodley Y, Moradi M, Moradi G, Moradi-Joo M, Moradi-Lakeh M, Moraga P, Mosapour A, Mouodi S, Mousavi S, Mozaffor M, Muluneh A, Muriithi M, Murray C, Murthy G, Musa K, Mustafa G, Muthupandian S, Naderi M, Nagarajan A, Naghavi M, Najafi F, Nangia V, Nazari J, Ndwandwe D, Negoi I, Ngunjiri J, Nguyen Q, Nguyen T, Nguyen C, Nigatu D, Ningrum D, Nnaji C, Nojomi M, Noubiap J, Oh I, Okpala O, Olagunju A, Bali A, Onwujekwe O, Ortega-Altamirano D, Osarenotor O, Osei F, Owolabi M, Mahesh P, Padubidri J, Pana A, Pashaei T, Pati S, Patle A, Patton G, Paulos K, Pepito V, Pereira A, Perico N, Pesudovs K, Pigott D, Piroozi B, Platts-Mills J, Poljak M, Postma M, Pourjafar H, Pourmalek F, Pourshams A, Poustchi H, Prada S, Preotescu L, Quintana H, Rabiee N, Rabiee M, Radfar A, Rafiei A, Rahim F, Rahimi-Movaghar V, Rahman M, Rajati F, Ramezanzadeh K, Rana S, Ranabhat C, Rasella D, Rawaf S, Rawaf D, Rawal L, Remuzzi G, Renjith V, Renzaho A, Reta M, Rezaei S, Ribeiro A, Rickard J, González C, Rios-Blancas M, Roever L, Ronfani L, Roro E, Rostami A, Rothenbacher D, Rubagotti E, Rubino S, Saad A, Sabour S, Sadeghi E, Safari S, Safdarian, Sagar R, Sahraian M, Sajadi S, Salahshoor M, Salam N, Salehi F, Zahabi S, Salem M, Salem H, Salimi Y, Salimzadeh H, Sambala E, Samy A, Sanabria J, Santos I, Saraswathy S, Sarker A, Sartorius B, Sathian B, Satpathy M, Sbarra A, Schaeffer L, Schwebel D, Senbeta A, Senthilkumaran S, Shabaninejad H, Shaheen A, Shaikh M, Shalash A, Shallo S, Shams-Beyranvand M, Shamsi M, Shamsizadeh M, Sharif M, Shey M, Shibuya K, Shiferaw W, Shigematsu M, Shil A, Shin J, Shiri R, Shirkoohi R, Si S, Siabani S, Singh J, Singh N, Sinha D, Sisay M, Skiadaresi E, Smith D, Sobhiyeh M, Sokhan A, Soofi M, Soriano J, Sorrie M, Soyiri I, Sreeramareddy C, Sudaryanto A, Sufiyan M, Suleria H, Sykes B, Tamirat K, Tassew A, Taveira N, Taye B, Tehrani-Banihashemi A, Temsah M, Tesfay B, Tesfay F, Tessema Z, Thankappan K, Thirunavukkarasu S, Thomas N, Tlaye K, Tlou B, Tovani-Palone M, Traini E, Tran K, Trihandini I, Ullah I, Unnikrishnan B, Tahbaz S, Valdez P, Varughese S, Veisani Y, Violante F, Vollmer S, Vos T, Wada F, Waheed Y, Wang Y, Wang Y, Weldesamuel G, Welgan C, Westerman R, Wiangkham T, Wijeratne T, Wiysonge C, Wolde H, Wondafrash D, Wonde T, Wu A, Xu G, Yadollahpour A, Jabbari S, Yamada T, Yaseri M, Yenesew M, Yeshaneh A, Yilma M, Yimer E, Yip P, Yirsaw B, Yisma E, Yonemoto N, Younis M, Yousof H, Yu C, Yusefzadeh H, Zamani M, Zambrana-Torrelio C, Zandian H, Zeleke A, Zepro N, Zewale T, Zhang D, Zhang Y, Zhao X, Ziapour A, Zodpey S, Hay S. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. The Lancet 2020, 395: 1779-1801. PMID: 32513411, PMCID: PMC7314599, DOI: 10.1016/s0140-6736(20)30114-8.Peer-Reviewed Original ResearchConceptsChild growth failureMiddle-income countriesBurden of diarrheaGeographical inequalitiesLow-incomeGlobal burdenRisk factorsGlobal Burden of Disease StudyBurden of Disease StudyGlobal Burden of DiseasePrevent childhood diarrheaPrecision public healthRisk Factors StudyRisk factor estimatesBurden of diseaseBetween-country variationBayesian model-based geostatisticsHigher risk of deathRisk of deathTherapy coveragePotential intervention strategiesHighest burdenVulnerable populationsLMICsDiarrhea prevalence
2015
The utility of the surprise question in identifying patients most at risk of death.
Vick J, Pertsch N, Hutchings M, Neville B, Lipsitz S, Gawande A, Block S, Bernacki R. The utility of the surprise question in identifying patients most at risk of death. Journal Of Clinical Oncology 2015, 33: 8-8. DOI: 10.1200/jco.2015.33.29_suppl.8.Peer-Reviewed Original ResearchSurprise questionRisk of deathOncology cliniciansSerious Illness Care ProgramEnd-of-life goalsEnd-of-lifeDana-Farber Cancer InstituteRandomized Controlled TrialsHigher risk of deathCare programPropensity score approachStructural interventionsPrediction of patient deathC-statisticCancer InstitutePredictive of deathComplete dataPatient deathDana-FarberCancer stageCliniciansIllness phasePredictive valueHigh riskProportion of survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply